cyc 202 has been researched along with (R)-DRF053 in 2 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies ((R)-DRF053) | Trials ((R)-DRF053) | Recent Studies (post-2010) ((R)-DRF053) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 7 | 0 | 6 |
| Protein | Taxonomy | cyc 202 (IC50) | (R)-DRF053 (IC50) |
|---|---|---|---|
| Glycogen synthase kinase-3 beta | Sus scrofa (pig) | 4.1 | |
| [Tau protein] kinase | Sus scrofa (pig) | 4.1 | |
| Cyclin-T1 | Homo sapiens (human) | 8 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 1.96 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 1.96 | |
| Cyclin-A2 | Homo sapiens (human) | 0.29 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.093 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.1915 | |
| Casein kinase I isoform alpha | Homo sapiens (human) | 0.014 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.822 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 8 | |
| Cyclin-H | Homo sapiens (human) | 0.822 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.822 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.1475 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.1475 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bettayeb, K; Demange, L; Ferandin, Y; Flajolet, M; Galons, H; Goddard, ML; Greengard, P; Lopez-Giral, A; Meijer, L; Mikros, E; Myrianthopoulos, V; Oumata, N | 1 |
| Abdellah, FN; Demange, L; Ferandin, Y; Galons, H; Gresh, N; Lozach, O; Meijer, L | 1 |
2 other study(ies) available for cyc 202 and (R)-DRF053
| Article | Year |
|---|---|
Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1.
Topics: Amyloid beta-Peptides; Animals; Binding Sites; Casein Kinase I; Cell Line; Cyclin-Dependent Kinases; Humans; Inhibitory Concentration 50; Models, Molecular; Protein Kinase Inhibitors; Purines; Roscovitine; Structure-Activity Relationship | 2008 |
Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling.
Topics: Binding Sites; Catalytic Domain; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase 5; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Purines; Roscovitine; Structure-Activity Relationship | 2013 |